PD‑1‑Positive Cells Contribute to the Diagnosis of Inflammatory Bowel Disease and Can Aid in Predicting Response to Vedolizumab
Kim et al., 2023
Anti–PD-1 Antibodies Recognizing the Membrane Proximal Region are PD-1 Agonists that can Downregulate Inflammatory Diseases
Suzuki et al., 2023
PD-1 and PD-1 Ligands: From Discovery to Clinical Application
Okazaki et al., 2020
Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial
Warren et al., 2023
Immune Checkpoint Inhibitor PD-1 Pathway is Down-Regulated in Synovium at Various Stages of Rheumatoid Arthritis Disease Progression
Guo et al., 2018
Coupling Mammalian Cell Surface Display With Somatic Hypermutation for the Discovery and Maturation of Human Antibodies
Bowers et al., 2011
Mammalian Cell Display for the Discovery and Optimization of Antibody Therapeutics
Bowers et al., 2014
Humanization of Antibodies Using Heavy Chain Complementarity-Determining Region 3 Grafting Coupled with in Vitro Somatic Hypermutation
Bowers et al., 2013
High Affinity Humanized Antibodies without Making Hybridomas; Immunization Paired with Mammalian Cell Display and In Vitro Somatic Hypermutation
McConnell et al., 2012
Preclinical Characterization of Dostarlimab, a Therapeutic Anti-PD-1 Antibody with Potent Activity to Enhance Immune Function in in Vitro Cellular Assays and in Vivo Animal Models
Kumar et al., 2021
The Majority of Generalized Pustular Psoriasis Without Psoriasis Vulgaris Is Caused by Deficiency of Interleukin-36 Receptor Antagonist
Sugiura et al., 2013
IL-36 in Psoriasis
Towne et al., 2012
IL-36: a Potential Psoriasis Target?
Raison et al., 2012
The Biochemistry of Somatic Hypermutation
Peled et al., 2005